Cargando…

Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer

SIMPLE SUMMARY: Prostate cancer cells produce lipids via the activation of a specific pathway called fatty acid synthesis, also known as De novo lipogenesis. This pathway is essential for the survival and growth of most types of cancer cells, including prostate cancer. In our study, we showed that p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lounis, Mohamed Amine, Péant, Benjamin, Leclerc-Desaulniers, Kim, Ganguli, Dwaipayan, Daneault, Caroline, Ruiz, Matthieu, Zoubeidi, Amina, Mes-Masson, Anne-Marie, Saad, Fred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7698241/ https://www.ncbi.nlm.nih.gov/pubmed/33187317 http://dx.doi.org/10.3390/cancers12113339

Ejemplares similares

Targeting IKKε in Androgen-Independent Prostate Cancer Causes Phenotypic Senescence and Genomic Instability
por: Gilbert, Sophie, et al.
Publicado: (2022)

Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance
por: Cahuzac, Maxime, et al.
Publicado: (2022)

Immune evasion strategies of neuroendocrine-like Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L, et al.
Publicado: (2013)

IKKε Inhibitor Amlexanox Promotes Olaparib Sensitivity through the C/EBP-β-Mediated Transcription of Rad51 in Castrate-Resistant Prostate Cancer
por: Gilbert, Sophie, et al.
Publicado: (2022)

Elevated Expression of Glycerol-3-Phosphate Phosphatase as a Biomarker of Poor Prognosis and Aggressive Prostate Cancer
por: Lounis, Mohamed Amine, et al.
Publicado: (2021)

Combined AKT and MEK Pathway Blockade in Pre-Clinical Models of Enzalutamide-Resistant Prostate Cancer
por: Toren, Paul, et al.
Publicado: (2016)

Pre-activation of autophagy impacts response to olaparib in prostate cancer cells
por: Cahuzac, Maxime, et al.
Publicado: (2022)

PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
por: Bishop, Jennifer L., et al.
Publicado: (2014)

Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality
por: Clairefond, Sylvie, et al.
Publicado: (2021)

Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity
por: Monga, Jitender, et al.
Publicado: (2021)

Galiellalactone inhibits the STAT3/AR signaling axis and suppresses Enzalutamide-resistant Prostate Cancer
por: Thaper, Daksh, et al.
Publicado: (2018)

PUMA and NOXA Expression in Tumor-Associated Benign Prostatic Epithelial Cells Are Predictive of Prostate Cancer Biochemical Recurrence
por: Clairefond, Sylvie, et al.
Publicado: (2020)

Enzalutamide inhibits testosterone-induced growth of human prostate cancer xenografts in zebrafish and can induce bradycardia
por: Melong, Nicole, et al.
Publicado: (2017)

Local and systemic modulation of the PD-L1 pathway is a novel mechanism of Enzalutamide resistance in castration-resistant prostate cancer
por: Bishop, Jennifer, et al.
Publicado: (2014)

Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer
por: Shiota, Masaki, et al.
Publicado: (2015)

Potential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay
por: Labouba, Ingrid, et al.
Publicado: (2015)

Enhanced killing of androgen-independent prostate cancer cells using inositol hexakisphosphate in combination with proteasome inhibitors
por: Diallo, J-S, et al.
Publicado: (2008)

Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials
por: Tombal, Bertrand F., et al.
Publicado: (2021)

De Novo Lipogenesis Products and Endogenous Lipokines
por: Yilmaz, Mustafa, et al.
Publicado: (2016)

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer
por: Zadra, Giorgia, et al.
Publicado: (2019)

Androgen-Regulated Expression of Arginase 1, Arginase 2 and Interleukin-8 in Human Prostate Cancer
por: Gannon, Philippe O., et al.
Publicado: (2010)

IκB-Kinase-epsilon (IKKε) over-expression promotes the growth of prostate cancer through the C/EBP-β dependent activation of IL-6 gene expression
por: Péant, Benjamin, et al.
Publicado: (2016)

Desaturation index versus isotopically measured de novo lipogenesis as an indicator of acute systemic lipogenesis
por: Harding, Scott V, et al.
Publicado: (2015)

ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer
por: Nouruzi, Shaghayegh, et al.
Publicado: (2022)

Expanding Roles of De Novo Lipogenesis in Breast Cancer
por: Simeone, Pasquale, et al.
Publicado: (2021)

DAXX drives de novo lipogenesis and contributes to tumorigenesis
por: Mahmud, Iqbal, et al.
Publicado: (2023)

The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials
por: Tombal, Bertrand, et al.
Publicado: (2021)

Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer
por: Tombal, B., et al.
Publicado: (2022)

Growth Hormone Inhibits Hepatic De Novo Lipogenesis in Adult Mice
por: Cordoba-Chacon, Jose, et al.
Publicado: (2015)

Direct Visualization of De novo Lipogenesis in Single Living Cells
por: Li, Junjie, et al.
Publicado: (2014)

Wnt signaling, de novo lipogenesis, adipogenesis and ectopic fat
por: Song, Kangxing, et al.
Publicado: (2014)

Regulation and Metabolic Significance of De Novo Lipogenesis in Adipose Tissues
por: Song, Ziyi, et al.
Publicado: (2018)

FASN-dependent de novo lipogenesis is required for brain development
por: Gonzalez-Bohorquez, Daniel, et al.
Publicado: (2022)

Fructose drives de novo lipogenesis affecting metabolic health
por: Geidl-Flueck, Bettina, et al.
Publicado: (2023)

Molecular Mechanisms of Enzalutamide Resistance in Prostate Cancer
por: Culig, Zoran
Publicado: (2017)

Molecular mechanisms of enzalutamide resistance in prostate cancer
por: Blatt, Eliot B., et al.
Publicado: (2019)

Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment
por: Attard, Gerhardt, et al.
Publicado: (2018)

HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer
por: Lu, Xiaodong, et al.
Publicado: (2022)

High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality
por: Dariane, Charles, et al.
Publicado: (2022)

De novo lipogenesis in metabolic homeostasis: More friend than foe?
por: Solinas, Giovanni, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_1anbk3mi2qmp0o5q1ur4lf9j5s